Study of Immune Responses to Influenza Vaccination

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03346772

Enrollment

150

Registered

2017-11-17

Start date

2017-10-20

Completion date

2026-07-01

Last updated

2026-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza Vaccination

Brief summary

Better understanding of the immune responses to influenza vaccination is needed in order to understand situations of poor vaccine response. Adults will receive influenza vaccination and then have peripheral blood drawn at pre-defined intervals in order to study the lymphocyte responses.

Interventions

BIOLOGICALInfluenza vaccination

Adults will receive one intramuscular dose of seasonal quadrivalent inactivated influenza vaccine, as indicated for standard of care.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Community-dwelling adults able to provide consent who need influenza vaccination for standard of care

Exclusion criteria

* febrile illness at time of vaccination * active malignancy * use of immunosuppressing medications * blood donation in the past 60 days * influenza vaccinated during the preceding 6 months * allergic reactions to influenza vaccination

Design outcomes

Primary

Measure	Time frame
Influenza neutralizing antibody titers	21-42 days

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORE.John Wherry, PhD

University of Pennsylvania

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 28, 2026